Sometimes good may come as a consequence of something terrible such as the atomic bomb explosions. Don Thomas's interest in bone marrow transplantation was sparked by research that followed development of the atomic bombs. Beginning in the 1940s, the US Government recruited scientists to the National Institutes of Health in Bethesda and the University of Chicago to participate in biological and medical research aspects of the Manhattan project. Their remit was determining ways to counter effects of radiation on humans, especially bone marrow failure. In 1950, Jacobsen and colleagues reported shielding of the spleen and later intra-peritoneal injection of spleen cells could ''protect'' an irradiated mouse from death. In 1952, Lorenz, Congden and Uphoff show infusing bone marrow cells could also rescue lethally irradiated mice and guinea pigs. Then in 1952, Main and Prehn showed that a chimera mouse would accept a skin graft from the bone marrow donor, and Ford used cytogenetics to prove hematopoietic recovery was from donor bone marrow cells. In 1962, Barnes, Loutit and Micklem described secondary disease (primary disease was graftrejection) which Simonsen in 1965 correctly identified as graft-versus-host-disease (GvHD). And in 1966, Billingham and Medawar laid out immunological requirements for graft-rejection and GvHD. The gauntlet was thrown and Don Thomas seized on these data and spent the rest of his life perfecting bone marrow transplants, first in dogs and later in persons with advanced leukaemia brought us to where we are today: 65,000-70,000 transplants are done each year worldwide. Thousands of lives are saved.
Many others contributed to development of bone marrow transplantation including Robert A. Good, George Santos, Fritz Bach, Richard Gatti, Mortimer Bortin, Dirk van Bekkum, Jon von Rood, Georges Mathe' and others whom I shall never be forgiven for not mentioning. All made important contributions but none stayed the course like Don Thomas. Quoting his wife (and secret weapon) Dottie Thomas: ''Don was indeed always patient, thorough and tenacious (some say stubborn). He did not give up easily and he truly enjoyed working at the bedside as well as in the theoretical aspects of transplantation.'' Don believed strongly in sharing fruits of his research and in international collaboration. He was a founding member of the International Bone Marrow Transplant Registry and had many Japanese colleagues and collaborators, especially Professors Ken-ichi Hattori and Fumimaro Takaku. Many Japanese transplant specialists trained with Don and his colleagues at Seattle and are now leaders in Japanese haematology. But I am especially grateful to Don Thomas for not having immediate space in his program for Professor Mine Harada who subsequently came to study at UCLA and became a life-time collaborator and friend. Another example of unintended consequences.
Don Thomas had a special fondness for Japan and for his Japanese colleagues and students. I know he will be greatly missed.
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